Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3026]

CB-839 in combination with cabozantinib in patients with clear cell and...

Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA

CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer ( Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA )

KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated...

Prof Evan Yu - Fred Hutchinson Cancer Research Center, Seattle, USA

KEYNOTE-365 Cohort A: Pembrolizumab plus olaparib in docetaxel-pretreated patients with mCRPC ( Prof Evan Yu - Fred Hutchinson Cancer Research Center, Seattle, USA )

ASCO GU 2019: Updates on treatment and management of bladder cancer

Professor Matthew Galsky, Professor Ananya Choudhury, Professor Joaquim...

ASCO GU 2019: Updates on treatment and management of bladder cancer ( Professor Matthew Galsky, Professor Ananya Choudhury, Professor Joaquim Bellmunt, Dr Andrea Necchi )

ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer

Prof Karim Fizazi, Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Nicholas...

ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer ( Prof Karim Fizazi, Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Nicholas Mottet )

STREAM trial: Enzalutamide and androgen deprivation therapy with salvage...

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA

STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC ( Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA )

Updates on metastatic bladder cancer from ASCO GU 2019

Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA

Updates on metastatic bladder cancer from ASCO GU 2019 ( Prof Arlene Siefker-Radtke - MD Anderson Cancer Center, Houston, USA )

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell...

Prof Brian Rini - Cleveland Clinic, Cleveland, USA

KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )

ASCO GU 2019 renal highlights

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO GU 2019 renal highlights ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC

Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA

ARCHES trial: Androgen deprivation therapy with enzalutamide or placebo in mHSPC ( Prof Andrew Armstrong - Duke Cancer Institute, Durham, USA )

Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma

Prof Brian Rini - Cleveland Clinic, Cleveland, USA

$Latest from Tivo-3: Tivozanib for refractory advanced renal cell carcinoma ( Prof Brian Rini - Cleveland Clinic, Cleveland, USA )$

Sacituzumab govitecan in patients with previously treated metastatic urothelial...

Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA

Sacituzumab govitecan in patients with previously treated metastatic urothelial cancer ( Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA )

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer

Dr Arjun Balar - NYU Langone Health, New York City, USA

Updates from KEYNOTE 57: Pembrolizumab for patients with bladder cancer ( Dr Arjun Balar - NYU Langone Health, New York City, USA )

More from ecancer